HSCYX
Price
$37.60
Change
-$0.54 (-1.42%)
Updated
Jul 13 closing price
Net Assets
711.1M
VSGIX
Price
$98.28
Change
-$1.41 (-1.41%)
Updated
Jul 13 closing price
Net Assets
47.01B
Interact to see
Advertisement

HSCYX vs VSGIX

HSCYX vs VSGIX Comparison Chart in %
View a ticker or compare two or three
VS
HSCYX vs. VSGIX commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HSCYX is a Buy and VSGIX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSGIX has more cash in the bank: 47B vs. HSCYX (711M). VSGIX pays higher dividends than HSCYX: VSGIX (0.42) vs HSCYX (0.00). HSCYX was incepted earlier than VSGIX: HSCYX (30 years) vs VSGIX (26 years). HSCYX (0.99) is less costly to investors than VSGIX (0.05). HSCYX is a more actively managed with annual turnover of: 71.00 vs. VSGIX (24.00). HSCYX has a lower initial minimum investment than VSGIX: HSCYX (250000) vs VSGIX (5000000). HSCYX annual gain was more profitable for investors over the last year : 32.94 vs. VSGIX (26.88). VSGIX return over 5 years is better than : 27.73 vs. HSCYX (-1.22).
HSCYXVSGIXHSCYX / VSGIX
Total Expense Ratio0.990.051,980%
Annual Report Gross Expense Ratio0.990.051,980%
Fund Existence30 years26 years-
Gain YTD16.49417.38395%
Front LoadN/AN/A-
Min. Initial Investment25000050000005%
Min. Initial Investment IRAN/AN/A-
Net Assets711M47B2%
Annual Yield % from dividends0.000.42-
Returns for 1 year32.9426.88123%
Returns for 3 years51.8951.28101%
Returns for 5 years-1.2227.73-4%
Returns for 10 years97.11181.6753%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HRCPX69.65N/A
N/A
Carillon ClariVest Capital Apprec A
WMMAX16.99N/A
N/A
TETON Westwood Mighty Mites A
SHPCX14.79N/A
N/A
Saratoga Health & Biotechnology C
ETCHX50.75N/A
N/A
Eventide Healthcare & Life Sciences C
PIIDX17.55N/A
N/A
Principal International Equity R-6